We present a patient with CLL who became resistant to multiple therapeutic regimens, which were associated with the emergence of IGH::CCND1 rearrangement and sequential acquisition of mutations in TP53, BTK, and BCL2 during disease progression. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.